4SC-205 is under clinical development by 4SC and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect 4SC-205’s likelihood of approval (LoA) and phase transition for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 06 Jun 2022 decreased 4SC-205’s Phase Transition Success Rate (PTSR) for Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their 4SC-205 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

4SC-205 overview

4SC-205 is under development for the treatment of solid tumors including hormone refractory prostate cancer, breast cancer refractory to hormone treatment, ovarian cancer, malignant melanoma, head and neck cancer, non-small cell lung cancer, bladder cancer, colorectal cancer, kidney cancer, relapsed and refractory multiple myeloma and malignant lymphomas. It is administered orally. The drug candidate is a small molecule inhibitor of the human kinesin spindle protein Eg5 which is of crucial importance for proper cell division (mitosis) by mediating chromosome separation to the daughter cells. The drug candidate is developed based on Virtual High Throughput Screening (vHTS) platform, 4SCan. It was under development for liver cancer and lung cancer.

It was under development for the treatment of liver and lung cancer in china and for liver cancer in United States.

4SC overview

4SC is a biopharmaceutical company that develops small molecule drugs for the treatment of cancer. The company’s product portfolio focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its small molecule product pipeline comprises of Resminostat and Domatinostat (4SC-202), both are histone deacetylase (HDAC) inhibitor. 4SC’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. The company develops and commercializes its products through partnerships and collaborations with pharmaceutical and biotech companies mainly in the European and Asian markets. 4SC is headquartered in Planegg-Martinsried, Germany.

Quick View 4SC-205 LOA Data

Report Segments
  • Innovator
Drug Name
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: 4SC
  • Originator: Nycomed
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.